Valence 로고
인기
로그인
Loading data for BCTXZ — first visit, this takes a few seconds.

관심목록에 추가

BriaCell Therapeutics Cor...

NasdaqCM: BCTXZ · 실시간 가격 · USD
0.10
+0.00 (0.00%)
종가 기준: Aug 24, 2026, 8:00 PM

주가와 핵심 숫자, 최신 뉴스를 한 곳에 모았습니다.

BriaCell Therapeutics Corp.(BCTXZ) 주가, 분석 및 데이터

0.00%

데이터 없음

매수호가0.93
시가총액n/a
매출 (ttm)n/a
순이익 (ttm)-30.68M
1.52
n/a
n/a
n/a
P/B (ttm)0.03
P/S (ttm)n/a
실적 발표일n/a
매도호가0.15
거래량37,643
평균 거래량 (20일)
시가0.12
전일 종가0.10
일중 범위0.10 - 0.17
52주 범위0.10 - 0.17
애널리스트n/a
목표주가n/a
배당n/a
배당락일n/a

BCTXZ 소개

BriaCell Therapeutics Corp., a pre-clinical stage immuno-oncology company, engages in developing targeted immunotherapies to transform cancer care. Its lead candidate is Bria-IMT, a targeted immunotherapy program against end-stage breast cancer that is in Phase 3 clinical trials. The company develops Bria-OTS, a personalized off-the-shelf immunotherapy; and a soluble CD80 protein therapeutic that acts as a stimulator of the immune system and an i...

[더 보기]
산업
섹터
IPO 일자 Jul 17, 2026
직원 수 n/a
상장 거래소 NasdaqCM
티커 BCTXZ
웹사이트 https://briacell.com
전체 기업 정보

재무 실적

2024년 BriaCell Therapeutics의 매출은 0로, 전년 0 대비 undefined% 증가했습니다. 순이익은 -4.79M로, -76.4% 감소했습니다.

재무제표
news image

1개월 전 · Simply Wall St.

Is CRA International’s New Bria-IMT Role Quietly Redefining Its Healthcare Moat and Pricing Power (CRAI)?

In July 2026, BriaCell Therapeutics Corp. announced it had engaged Charles River Associates (CRA International) and Kaleio, Inc. to support commercial strategy, market access evaluation, and brand pla...

news image

2개월 전 · MT Newswires

BriaCell Presenting Final Phase 2, Ongoing Phase 3 Data at ASCO Meeting

BriaCell Therapeutics (BCT.TO) Monday said it is presenting final Phase 2 data from its Bria-IMT tri

news image

3개월 전 · MT Newswires

BriaCell Therapeutics Completes Manufacturing Bria-PROS+ Clinical Supplies

BriaCell Therapeutics (BCT.TO), down near 1% in U.S. pre-market trade, has completed manufacturing

news image

3개월 전 · MT Newswires

BriaCell Says FDA Clears Way For Bria-BRES+ Phase 1/2a Study

BriaCell Therapeutics (BCT.TO) has received FDA approval to initiate clinical evaluation of its next

news image

7개월 전 · MT Newswires

Top Midday Decliners

TryHard (THH) unveiled on Wednesday an equity purchase agreement in which Summer Explorer Investment

2 페이지 중 1